61 completed, 38 terminated, 20 active not recruiting, 16 recruiting. 157 Phase 1, 63 Phase 2.
Follow Metastatic Melanoma: new trials by email Literature Review of Metastatic Melanoma trials Research Report on Metastatic Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-11-01 | 2026-10-30 |
| IL-17 Blockade to Decrease irAEs (REPLAY) Secukinumab Injection - Metastatic Melanoma | Phase 1 | Recruiting | Duke University | 4 | 2026-03-12 | 2026-11-06 |
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Atezolizumab - Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2025-11-04 | 2026-10-16 |
| NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis NovoTTF-200A, Pembrolizumab - Metastatic Melanoma, Melanoma Brain Metastasis | Phase 1 / Phase 2 | Withdrawn | Brown University | 2025-10-30 | 2026-01-02 | |
| Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung Aerosol Sargramostim, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung | Phase 1 | Withdrawn | Mayo Clinic | 2025-10-28 | 2025-08-07 | |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma Adze1.C - Metastatic Melanoma | Phase 1 | Recruiting | Adze Biotechnology Australia Pty Ltd | 30 | 2025-10-01 | 2026-07-08 |
| TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma TILT-123, TIL, Cyclophosphamide - Metastatic Melanoma | Phase 1 | Active not recruiting | TILT Biotherapeutics Ltd. | 9 | 2025-06-25 | 2026-03-05 |
| A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors PF-08046031 - Malignant Melanoma, Melanoma | Phase 1 | Terminated | Pfizer | 11 | 2025-05-01 | 2026-03-18 |
| A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel IOV-3001 - Unresectable Melanoma, Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 42 | 2025-03-11 | 2026-06-15 |
| Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors Cytokine-induced memory-like natural killer cells, Relatilmab, Nivolumab - Advanced Melanoma, Metastatic Melanoma | Phase 1 | Recruiting | Washington University School of Medicine | 33 | 2024-11-06 | 2026-10-23 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma AK104+Axitinib, AK112+Axitinib - Melanoma, Mucosal Melanoma | Phase 1 | Enrolling by invitation | Peking University Cancer Hospital & Institute | 60 | 2024-05-28 | 2026-07-13 |
| Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma PV-001-DC - Metastatic Melanoma | Phase 1 | Unknown | PrimeVax Immuno-Oncology Inc. | 10 | 2024-04-01 | 2023-07-06 |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors OBX-115 - Tumor Skin, Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Obsidian Therapeutics, Inc. | 254 | 2023-10-25 | 2026-11-03 |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma [203Pb]VMT01, [212Pb]VMT01, Nivolumab - Recurrent Melanoma (Skin), Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-06-01 | 2026-10-13 |
| Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain Natural Killer Cell Therapy, Temozolomide - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain | Phase 1 / Phase 2 | Recruiting | Kari Kendra | 24 | 2023-03-01 | 2026-06-11 |
| XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy XmAb22841, XmAb23104 - Metastatic Melanoma, Advanced Melanoma | Phase 1 | Terminated | University of California, San Francisco | 6 | 2023-02-28 | 2025-03-26 |
Showing 20 of 157. Sign in to see all of them.
Melanoma (157) · Neoplasm Metastasis (26) · Carcinoma, Non-Small-Cell Lung (23) · Lung Neoplasms (13) · Carcinoma, Renal Cell (12) · Neoplasms (12) · Uveal Melanoma (12) · Brain Neoplasms (10) · Breast Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (7) · Carcinoma, Hepatocellular (6) · Carcinoma, Transitional Cell (6) · Ovarian Neoplasms (6) · Skin Neoplasms (6) · Colorectal Neoplasms (5)
Neoplasms by Histologic Type (157) · Neoplasms by Site (157) · Neoplasms, Germ Cell and Embryonal (157) · Neoplasms, Nerve Tissue (157) · Neuroectodermal Tumors (157) · Nevi and Melanomas (157) · Skin Diseases (157) · Skin and Connective Tissue Diseases (157) · Neuroendocrine Tumors (156) · Skin Neoplasms (151) · Neoplasms (145) · Neoplasms, Glandular and Epithelial (31) · Pathologic Processes (27) · Pathological Conditions, Signs and Symptoms (27) · Carcinoma (26)
Nivolumab (31) · Ipilimumab (24) · pembrolizumab (23) · Cyclophosphamide (20) · Specimen Handling (14) · Magnetic Resonance Spectroscopy (13) · fludarabine (13) · Biopsy (11) · CTLA-4 Antigen (11) · Interleukin-2 (11) · Temozolomide (11) · dabrafenib (9) · fludarabine phosphate (9) · aldesleukin (8) · trametinib (8)
National Cancer Institute (NCI) (20) · M.D. Anderson Cancer Center (12) · Mayo Clinic (9) · Hoffmann-La Roche (3) · Inge Marie Svane (3) · Ludwig Institute for Cancer Research (3) · Pierre Fabre Medicament (3) · BioNTech US Inc. (2) · Bristol-Myers Squibb (2) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (2) · Duke University (2) · Emory University (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Iovance Biotherapeutics, Inc. (2) · Jonsson Comprehensive Cancer Center (2)
United States (121) · France (12) · Australia (10) · Spain (10) · Denmark (7) · Belgium (5) · United Kingdom (5) · Canada (4) · Israel (4) · Italy (4) · Netherlands (3) · Germany (2) · New Zealand (2) · South Korea (2) · Switzerland (2)
Steven A Rosenberg, M.D. (6) · Anna Pavlick, DO (2) · Antoni Ribas, MD, PhD (2) · Eithan Galun, M.D. (2) · Evan J Lipson (2) · Ezra Cohen, MD (2) · Inge Marie Svane (2) · Inge Marie Svane, Prof., MD (2) · Jedd Wolchok, MD, PhD (2) · Marina Klein, MD (2)
PMID 32747469, PMID 15944250, PMID 16882708, PMID 22056381, PMID 22658127, PMID 22864522, PMID 23377668, PMID 23676418, PMID 23861247, PMID 23934126, PMID 24590637, PMID 25062770, PMID 25695689, PMID 28428884, PMID 28497258, PMID 29552014, PMID 30154193, PMID 30689736, PMID 31154457, PMID 31343665, PMID 31355467, PMID 31401903, PMID 31744895, PMID 32192573, PMID 32322662, PMID 32503950, PMID 33294860, PMID 33513935, PMID 33643689, PMID 33909232, PMID 33914706, PMID 34413169, PMID 34562230, PMID 34772758, PMID 34887574, PMID 34965890, PMID 35080914, PMID 35264434, PMID 35780243, PMID 36821617, PMID 36934257, PMID 36997799, PMID 37042037, PMID 37129197, PMID 37217243, PMID 37219686, PMID 37590001, PMID 37739939, PMID 38236249, PMID 38252910
U01CA062490 (4), UM1CA186709 (4), 2019 (3), 2018 (2), P30CA006516 (2), P30CA138292 (2), UM1CA186691 (2), UM1CA186704 (2), 2009 (1), 2016 (1), 2023 (1), P30CA015083 (1), P30CA015704 (1), P30CA016042 (1), P30CA016056 (1)